# Shanghai Yingli Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-yingli-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.yl-pharma.com
- Total disclosed funding: $30M
- Latest round: Series A (Feb 2, 2021)
- Investors on record: 3

## About

Established in 2011 and based in Shanghai, China, Shanghai Yingli Pharmaceutical Co., Ltd. is a medical company that engages in the research and development of small molecule drugs for the treatment of cancer, autoimmune diseases and metabolic disorders. The company also received new drug marketing approval from the National Drug Administration (NMPA) in November 2022 for its self-developed Linperlisib tablets, under the trade name Intarex®.

The company is dedicated to the research and development of clinically unmet needs and focuses on the development of innovative chemical small molecule drugs with proprietary intellectual property rights for the treatment of cancer, autoimmune diseases and metabolic diseases, with its main products being the three types of inhibitors, namely YY-20394, YL-90148, and YL-13027.

## Funding rounds

- Series A, Feb 2, 2021, $30M — Shanghai Zhangjiang Science & Technology Venture Capital, South China Venture Capital, Hongsen Investment

## Investors

- Shanghai Zhangjiang Science & Technology Venture Capital — Series A
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series A
- Hongsen Investment (https://capitalatlas.ai/funds/hongsen-investment) — Series A